Guan S-S, Sheu M-L, Yang R-S, Chan D-C, Wu C-T, Yang T-H, et al
Disruption of the gut microbiome and intestinal motility by Candida's invasive hyphae produces irregular peristalsis, often mimicking or co-existing with irritable bowel syndrome
Meanwhile, tirzepatide, approved by the FDA in 2022 for type 2 diabetes and obesity, has shown remarkable efficacy in weight management, with clinical trials reporting an average weight loss of 22.5% over 72 weeks (SURPASS-2 trial, 2023)
A: Common side effects include mild flushing, headache, or injection site reactions, typically resolving within 30 minutes
The critical variable is whether the specific pharmacy can provide lot-level documentation particularly the benzyl alcohol assay and sterility confirmation for the product currently in distribution
Patients should be educated on appropriate administration techniques for each